Johnson & Johnson (NYSE:JNJ) – Equities researchers at Jefferies Group boosted their FY2018 EPS estimates for shares of Johnson & Johnson in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $8.31 per share for the year, up from their previous estimate of $8.17. Jefferies Group currently has a “Buy” rating and a $160.00 price target on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2022 earnings at $11.58 EPS.

JNJ has been the subject of several other research reports. Cowen reiterated an “outperform” rating and issued a $155.00 target price (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Barclays upped their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $145.94.

Johnson & Johnson (NYSE:JNJ) traded up $0.12 during midday trading on Wednesday, hitting $146.98. 10,618,239 shares of the stock traded hands, compared to its average volume of 6,299,060. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The company has a market cap of $394,860.00, a price-to-earnings ratio of 25.52, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the business posted $1.68 EPS. The business’s revenue was up 10.3% compared to the same quarter last year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.29%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Harding Loevner LP purchased a new stake in Johnson & Johnson during the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after buying an additional 5 shares in the last quarter. IHT Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson in the second quarter worth about $124,000. 65.71% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/17/brokers-set-expectations-for-johnson-johnsons-fy2018-earnings-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.